NDC product
Zidovudine
NDC 65862-107 · Aurobindo Pharma Limited
Key facts
| Product NDC | 65862-107 |
|---|---|
| Proprietary name | Zidovudine |
| Nonproprietary name | Zidovudine |
| Substances | ZIDOVUDINE |
| Dosage form | CAPSULE |
| Route | ORAL |
| Labeler | Aurobindo Pharma Limited |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA078128 |
| Pharmacologic classes | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| Marketing start | Mar 27, 2006 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: